Interesting update on Newron Pharmaceuticals Inc, and Italian company working in Parkinson's disease. The have an implantable pump that will circulate a human growth factor that they believe can help stimulate control of dopamine levels in PD patients.
http://pharmatimes.com/Article/15-01-14/Newron_puts_non-oral_Parkinson_s_therapy_into_Phase_II.aspx
ISCO believe that the expression of trophic factors is an important part of the mechanism of action of neural stem cell transplants, so it will be interested to see the results from the Newron trial.
Thursday, January 15, 2015
As PD trail approaches, ISCO featured in the UT
International Stem Cell Corporation was featured by biotech writer Brdley Fikes in yesterday's San Diego Union Tribune.
http://www.utsandiego.com/news/2015/jan/14/parkinsons-stem-cell-parthenogenetic/
As we approach the initiation of our first clinical trial and the first stem cell trial in Parkinson's disease the amount of media interest will undoubtedly increase.
http://www.utsandiego.com/news/2015/jan/14/parkinsons-stem-cell-parthenogenetic/
As we approach the initiation of our first clinical trial and the first stem cell trial in Parkinson's disease the amount of media interest will undoubtedly increase.
Subscribe to:
Posts (Atom)